Skye BioscienceSKYE
SKYE
About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Employees: 16
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $84K | Put options by funds: $21K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
3% more funds holding
Funds holding: 73 [Q4 2024] → 75 (+2) [Q1 2025]
3.36% less ownership
Funds ownership: 83.09% [Q4 2024] → 79.73% (-3.36%) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
45% less capital invested
Capital invested by funds: $71.3M [Q4 2024] → $39.3M (-$32M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
583%
upside
Avg. target
$14.50
607%
upside
High target
$15
632%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Albert Lowe | 583%upside $14 | Buy Maintained | 21 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben | 632%upside $15 | Market Outperform Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about SKYE published over the past 30 days
Positive
Zacks Investment Research
3 weeks ago
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Neutral
GlobeNewsWire
3 weeks ago
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:
Positive
Proactive Investors
3 weeks ago
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience
Shares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-stage obesity drug. The Cambridge-based firm will apply its proprietary Arestat technology to create a more concentrated version of nimacimab, a monoclonal antibody that targets the CB1 receptor, which plays a role in appetite and metabolism.
Positive
Proactive Investors
3 weeks ago
Arecor partners with Skye Bioscience to improve formulation of obesity drug
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experimental obesity treatment, as drugmakers vie for a share of the fast-growing weight-loss market. The Cambridge-based company will use its proprietary Arestat technology to reformulate nimacimab, a monoclonal antibody developed by Skye that targets the CB1 receptor.
Neutral
GlobeNewsWire
3 weeks ago
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Neutral
GlobeNewsWire
1 month ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, presented a clinical pharmacokinetic (“PK”) and pharmacodynamic (“PD”) model that underscores the fundamental relationship between biodistribution and efficacy of CB1 inhibitors at the annual European Congress on Obesity meeting. This model demonstrated that achieving strong peripheral CB1 inhibition is sufficient to achieve efficacy, including weight loss.
Neutral
Seeking Alpha
1 month ago
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive Officer Chris Twitty - Chief Scientific Officer Kaitlyn Arsenault - Chief Financial Officer Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Conference Call Participants Jay Olson - Oppenheimer Albert Lowe - Craig-Hallum Ted Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Andy Hsieh - William Blair Jon Wolleben - Citizens JMP Bernie Hertel Hello, and thank you all for participating in today's call. Joining me today is Punit Dhillon, Skye's President and CEO; Chris Twitty, CSO, and Kaitlyn Arsenault, Skye's CFO.
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2025, along with key accomplishments and upcoming milestones.
Neutral
GlobeNewsWire
1 month ago
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th.
Charts implemented using Lightweight Charts™